Consequently, treatment with AAV2/9 vectors that reduces PMP22 levels in mSC constitutes an efficient and long-term preventive treatment for CMT1A symptoms in rats. The gene discussed is PMP22; the disease is Charcot-Marie-Tooth disease type 1A.